Intraoperative floppy iris syndrome

disease
On this page

Summary

Intraoperative floppy iris syndrome (MONDO:0041775) is a disease and 8 clinical trials. Top therapeutic interventions include brimonidine tartrate, epinephrine, and racepinephrine. A subtype of iris disorder — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

  • Clinical trials: 8

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

FieldValue
Canonical nameintraoperative floppy iris syndrome
Mondo IDMONDO:0041775
ICD-10-CMH21.81
SNOMED CT418801006
UMLSC1688637
MedGen739048
Is cancer (heuristic)no

Also known as: intraoperative floppy iris syndrome

Disease family

This is a subtype of iris disorder. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › disorder of orbital regioneye disorderuveal disorderiris disorderintraoperative floppy iris syndrome

Related subtypes (7): pupil disorder, ciliary body disorder, iritis, exfoliation syndrome, aniridia, iris neoplasm, anterior segment dysgenesis 3

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 8.

Phase distribution (across all retrieved trials)

PhaseTrials
Not specified5
PHASE41
PHASE31
PHASE21

Top trials by phase / activity

NCTPhaseStatusTitle
NCT06266962PHASE4COMPLETEDComparing the Efficiency of Two Approaches in Patients at Risk of Developing Intraoperative Floppy Iris Syndrome
NCT02093689PHASE3TERMINATEDIntraoperative Floppy Iris Syndrome Undergoing Intraocular Lens Replacement Surgery
NCT03760185PHASE2COMPLETEDPupil Dilation for Treatment of IFIS
NCT00627913Not specifiedTERMINATEDRetrobulbar Injection of Anesthesia Versus Healon 5 in the Management of Intraoperative Floppy Iris Syndrome
NCT01070602Not specifiedUNKNOWNThe Effect of Anterior Corneal Incisions on Intraoperative Floppy Iris Syndrome (IFIS) Incidence and Severity in Tamsulosin Treated Cataract Patients
NCT01693575Not specifiedCOMPLETEDUse of APX 100 Device for Small-pupil Cataract Surgery and Intraoperative Floppy-iris Syndrome
NCT01704014Not specifiedCOMPLETEDIntraoperative Floppy Iris Syndrome in Korean Patients Taking α1-Adrenergic Receptor Antagonists
NCT07517094Not specifiedCOMPLETEDPupillary Dilator Muscle Thickness as a Potential Predictor of Intraoperative Floppy Iris Syndrome

Drugs tested across these trials (top 30)

MoleculeMax phaseTrials referencing
BRIMONIDINE TARTRATE41
EPINEPHRINE41
RACEPINEPHRINE21